A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm
G
Greg Durm, MD
Primary Investigator
Overview
This is a research study to find out if giving a drug called pembrolizumab after lung cancer surgery does a better job at keeping the cancer from coming back than surgery alone.
Description
Participants in this study will be assigned by chance to be watched closely by their doctor or to receive a drug called pembrolizumab. Pembrolizumab is given as an infusion in the clinic once every three weeks. Participants will have tests, exams and procedures that are part of regular care and for study purposes. Participants will also have scans every 12 weeks to make sure the cancer hasn’t come back. If assigned to receive pembrolizumab, participants can continue to receive it for up to 1 year.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
non-small cell lung cancer (NSCLC)
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age who have undergone surgical resection of their stage I NSCLC.
Individuals who have previous chemotherapy, radiation, or immunotherapy for this lung cancer will not be eligible.
Individuals with immunodeficiency or autoimmune disorder will not be eligible.
Women who are pregnant or breastfeeding will not be eligible.
Updated on
01 May 2024.
Study ID: 2002147672
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
